Skip to content

Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy

Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00955500
Enrollment
116
Registered
2009-08-10
Start date
2003-01-31
Completion date
2009-01-31
Last updated
2009-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Encephalopathy

Keywords

Hepatic encephalopathy, Cirrhosis, Proteins of the diet, Branched-chain amino acids

Brief summary

The purpose of this study is to compare a normal-protein diet containing branched-chain amino acids to a low-protein diet in patients with non-terminal cirrhosis (MELD \< 25) who have developed an episode of hepatic encephalopathy within two months prior to inclusion.

Detailed description

Hepatic encephalopathy is a major complication of cirrhosis associated with poor prognosis and poor quality of life. Appearance of HE occurs in the setting of precipitating factors that increase plasma ammonia. The gastrointestinal tract is the primary source of ammonia, which is produced by enterocytes from glutamine and by colonic bacterial catabolism of nitrogenous sources, such as ingested proteins. This is the rationale for proposing low-protein diet as strategy to reduce ammonia production and as standard diet in patients with cirrhosis and hepatic encephalopathy. However, low-protein diet could cause wasting muscle and predispose to recurrence of hepatic encephalopathy, since muscle is an important site for extrahepatic ammonia removal. Branched-chain amino acids have shown beneficial effects on mental state of patients with chronic hepatic encephalopathy. The possible mechanism of action may be improvement of nutritional status through induction of protein synthesis. However, role of branched-chain amino acids in treatment and prevention of acute hepatic encephalopathy is not established. Administration of a normal-protein diet containing oral branched-chain amino acids may reduce recurrence of hepatic encephalopathy as compared to a low-protein diet.

Interventions

DIETARY_SUPPLEMENTBranched-chain amino acids

30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily

DIETARY_SUPPLEMENTMaltodextrin

30 grams of oral maltodextrin daily

Sponsors

Hospital Universitari Vall d'Hebron Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Cirrhosis of the liver. * Recovery from an episode of hepatic encephalopathy within two months prior to inclusion. * Compliance with a standard diet during two weeks prior to inclusion.

Exclusion criteria

* End-stage cirrhosis (MELD score \> 25). * Marked cognitive disorder (mini-mental test \< 27). * Non-treatable hepatocarcinoma in accordance with Milan criteria. * Comorbid conditions with a life expectancy less than 6 months. * Neurological conditions that difficult assessment of treatment of hepatic encephalopathy (dementia, encephalitis, severe depression). * Diseases requiring administration of a specific diet (malabsorption, chronic diarrhea, chronic pancreatic insufficiency, severe obesity). * No acceptation of written consent.

Design outcomes

Primary

MeasureTime frame
Hepatic encephalopathy-free survival56 weeks

Secondary

MeasureTime frame
Overall duration in days of episodic hepatic encephalopathy56 weeks
Minimal hepatic encephalopathy assessed by neuropsychological tests56 weeks
Health-related quality of life56 weeks
Nutritional status56 weeks
Liver function56 weeks

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026